Investor Presentation

135 Investor presentation First six months of 2022 Novo Nordisk volume market shares in the three insulin segments NAO USA long-acting insulin USA premix insulin USA fast-acting insulin tMU tMU tMU 100 80% 80 80% 80 100% CAGR volume1: 0.5% MI penetration²: 65.4% CAGR volume1: -7.2% MI penetration²: 47.8% CAGR volume1: 1.9% MI penetration²: 83.6% 80 60% 60 80% 60 60% 60 60 60 40 40 20 20 0 40% 40 40 20% 20 40% 40 20% 20 0% 0 May May 2022 2017 0% 0 May May May 2017 2022 2017 Ⓡ Segment volume Tresiba -Levemir Segment volume Combined NovoLog Mix share 70/30 1 CAGR for 5-year period; 2 Includes new-generation insulin. tMU: Thousand mega units Source: IQVIA monthly MAT, May 2022 volume figures NN: Novo Nordisk Segment volume Ⓡ Fiasp 60% 40% 20% 0% May 2022 Ⓡ -NovoRapid NN combined

View entire presentation